Immatics (IMTX) Competitors $5.82 -0.10 (-1.69%) Closing price 04:00 PM EasternExtended Trading$5.88 +0.05 (+0.95%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock IMTX vs. TARS, OGN, ALVO, CNTA, DNLI, IBRX, AGIO, IDYA, OCUL, and HRMYShould you be buying Immatics stock or one of its competitors? The main competitors of Immatics include Tarsus Pharmaceuticals (TARS), Organon & Co. (OGN), Alvotech (ALVO), Centessa Pharmaceuticals (CNTA), Denali Therapeutics (DNLI), ImmunityBio (IBRX), Agios Pharmaceuticals (AGIO), IDEAYA Biosciences (IDYA), Ocular Therapeutix (OCUL), and Harmony Biosciences (HRMY). These companies are all part of the "pharmaceutical products" industry. Immatics vs. Its Competitors Tarsus Pharmaceuticals Organon & Co. Alvotech Centessa Pharmaceuticals Denali Therapeutics ImmunityBio Agios Pharmaceuticals IDEAYA Biosciences Ocular Therapeutix Harmony Biosciences Immatics (NASDAQ:IMTX) and Tarsus Pharmaceuticals (NASDAQ:TARS) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations. Which has more volatility and risk, IMTX or TARS? Immatics has a beta of 1.02, suggesting that its share price is 2% more volatile than the S&P 500. Comparatively, Tarsus Pharmaceuticals has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500. Is IMTX or TARS more profitable? Tarsus Pharmaceuticals has a net margin of -31.13% compared to Immatics' net margin of -59.29%. Immatics' return on equity of -15.60% beat Tarsus Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Immatics-59.29% -15.60% -12.31% Tarsus Pharmaceuticals -31.13%-32.36%-21.04% Do analysts rate IMTX or TARS? Immatics currently has a consensus price target of $14.67, suggesting a potential upside of 152.00%. Tarsus Pharmaceuticals has a consensus price target of $66.67, suggesting a potential upside of 35.06%. Given Immatics' stronger consensus rating and higher probable upside, equities analysts clearly believe Immatics is more favorable than Tarsus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Immatics 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.83Tarsus Pharmaceuticals 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.71 Does the media favor IMTX or TARS? In the previous week, Tarsus Pharmaceuticals had 2 more articles in the media than Immatics. MarketBeat recorded 8 mentions for Tarsus Pharmaceuticals and 6 mentions for Immatics. Tarsus Pharmaceuticals' average media sentiment score of 1.11 beat Immatics' score of 1.03 indicating that Tarsus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immatics 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tarsus Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has preferable earnings & valuation, IMTX or TARS? Immatics has higher earnings, but lower revenue than Tarsus Pharmaceuticals. Tarsus Pharmaceuticals is trading at a lower price-to-earnings ratio than Immatics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioImmatics$168.65M4.19$16.47M-$0.65-8.95Tarsus Pharmaceuticals$182.95M11.39-$115.55M-$2.33-21.18 Do insiders and institutionals hold more shares of IMTX or TARS? 64.4% of Immatics shares are owned by institutional investors. Comparatively, 90.0% of Tarsus Pharmaceuticals shares are owned by institutional investors. 3.3% of Immatics shares are owned by insiders. Comparatively, 9.0% of Tarsus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. SummaryImmatics beats Tarsus Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Get Immatics News Delivered to You Automatically Sign up to receive the latest news and ratings for IMTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding IMTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMTX vs. The Competition Export to ExcelMetricImmaticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$707.42M$3.12B$5.78B$10.15BDividend YieldN/A2.32%5.69%4.61%P/E Ratio-8.9521.3074.5925.92Price / Sales4.19258.41453.9085.92Price / Cash23.7845.3337.0859.91Price / Book1.149.6112.156.29Net Income$16.47M-$53.29M$3.28B$270.85M7 Day Performance-7.03%0.29%0.98%3.36%1 Month Performance-9.35%8.91%7.20%6.41%1 Year Performance-53.29%13.14%63.06%28.26% Immatics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMTXImmatics2.92 of 5 stars$5.82-1.7%$14.67+152.0%-49.4%$719.58M$168.65M0.00260Positive NewsTARSTarsus Pharmaceuticals2.7501 of 5 stars$58.58+0.7%$66.67+13.8%+63.1%$2.47B$182.95M-25.1450Positive NewsInsider TradeOGNOrganon & Co.4.6468 of 5 stars$9.40+2.3%$18.00+91.6%-47.1%$2.45B$6.40B3.494,000Positive NewsALVOAlvotech3.2488 of 5 stars$8.07+0.2%$14.00+73.5%-25.2%$2.43B$491.98M35.091,032Short Interest ↓CNTACentessa Pharmaceuticals3.2033 of 5 stars$16.79+1.4%$31.50+87.6%+64.9%$2.25B$6.85M-9.38200Insider TradeDNLIDenali Therapeutics4.3728 of 5 stars$15.27-2.4%$33.62+120.1%-45.3%$2.23B$330.53M-5.45430Positive NewsIBRXImmunityBio2.5035 of 5 stars$2.34+0.4%$10.75+359.4%-28.5%$2.21B$14.74M-4.87590Analyst ForecastAGIOAgios Pharmaceuticals4.3264 of 5 stars$37.71-1.2%$56.33+49.4%-17.6%$2.19B$36.50M3.43390Insider TradeIDYAIDEAYA Biosciences3.9843 of 5 stars$24.55-1.5%$47.10+91.9%-31.1%$2.15B$7M-6.4880Trending NewsAnalyst ForecastAnalyst RevisionOCULOcular Therapeutix3.928 of 5 stars$12.21-2.5%$17.20+40.9%+51.3%$2.12B$63.72M-9.54230HRMYHarmony Biosciences4.6032 of 5 stars$36.89-2.8%$51.00+38.2%-10.4%$2.12B$714.73M11.90200Positive News Related Companies and Tools Related Companies Tarsus Pharmaceuticals Competitors Organon & Co. Competitors Alvotech Competitors Centessa Pharmaceuticals Competitors Denali Therapeutics Competitors ImmunityBio Competitors Agios Pharmaceuticals Competitors IDEAYA Biosciences Competitors Ocular Therapeutix Competitors Harmony Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:IMTX) was last updated on 9/12/2025 by MarketBeat.com Staff From Our PartnersCritical AI announcement set to ignite AI 2.0I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredDo NOT Day Trade (Do THIS instead)Forget day trading (especially in markets like these). Trade OVERNIGHT instead! I've uncovered a shockin...Monument Traders Alliance | SponsoredWall Street laughed at Trump’s “Smart Dollar.” Now they’re all in."THIS is the Biggest Economic Story of 2025" While most Americans are focused on tariffs and inflation, the...Stansberry Research | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredAlert: Prepare for Trump's Dollar OverhaulPresident Trump just signed a game-changing law… That could soon upgrade the U.S. dollar in your checking a...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immatics N.V. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immatics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
